• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

    7/16/25 6:35:00 PM ET
    $MSFT
    $PSNL
    $TEM
    $TVGN
    Computer Software: Prepackaged Software
    Technology
    Medical Specialities
    Health Care
    Get the next $MSFT alert in real time by email

    Equity Insider News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and geographic region play a major role in shaping patient attitudes—and that the score could be used to tailor AI-driven tools in a way that improves both outcomes and satisfaction. With the global AI healthcare market projected to exceed $110 billion by 2030, companies such as Avant Technologies, Inc. (OTCQB:AVAI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), Microsoft Corporation (NASDAQ:MSFT), Personalis, Inc. (NASDAQ:PSNL), and Tempus AI, Inc. (NASDAQ:TEM).

    Equity Insider Logo (PRNewsfoto/Equity Insider)

    AI could inject an additional $461 billion into the healthcare sector by 2035, according to Accenture, as it races past the $2.26 trillion mark. This shift isn't just about diagnostics or robotics—it's about rewiring the entire healthcare ecosystem from the inside out, and multiple companies are positioning themselves to capitalize on the shift.

    Avant Technologies, Inc. (OTCQB:AVAI) and joint-venture partner Ainnova Tech reached a pivotal regulatory milestone in their pursuit of AI-driven healthcare disruption—completing a key pre-submission meeting with the U.S. Food and Drug Administration (FDA) for their flagship diagnostic platform, Vision AI, the companies' flagship diagnostic platform for diabetic retinopathy and other retinal diseases.

    "We're truly excited about this next phase," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. "We're getting ready to begin data collection across primary care clinics in the U.S. with a study that is simple, yet rigorous—comparing our AI-based retinal screening to the readings of three retinologists.

    The July 15 meeting marked a critical step toward securing 510(k) clearance for Vision AI, which screens for diabetic retinopathy using artificial intelligence and retinal imaging. The session provided Ainnova and its clinical trial partner, Fortrea, with detailed guidance from the FDA, including feedback on study design, number of participating clinics, retinologist involvement, and trial execution strategy. With this roadmap in place, the team can now finalize its U.S. trial plan and begin preparing for formal data collection—bringing Vision AI closer to commercialization in the world's largest healthcare market.

    "This milestone not only brings us closer to validating our platform in the world's largest healthcare market, but it also paves the way for the upcoming approval of our new automated retinal camera," added Vargas. "We believe will [it] be a game changer—making diabetic retinal screenings faster, more accessible, and available from virtually any point of care."

    The FDA development comes just as Avant and Ainnova officially launch a first-of-its-kind chronic care model across Latin America, focused on preventive screening for patients with diabetes and other systemic conditions. The initiative—now live through pilot programs with Grupo Dökka's Fischel and La Bomba pharmacy chains—offers free, walk-in retinal risk assessments at local pharmacies. It's a bold attempt to break down long-standing access barriers by bypassing the need for specialist appointments altogether.

    Instead, patients receive real-time results through Ainnova's AI platform, with those flagged as "at risk" referred seamlessly into a growing network of clinics and specialists. The model has already gained traction among pharmacies, insurers, and pharmaceutical partners—demonstrating a rare alignment of incentives across the healthcare ecosystem.

    Over 30% of diabetics develop diabetic retinopathy, a condition that's treatable when caught early, but which remains the leading cause of preventable blindness worldwide. The Vision AI system enables earlier, lower-cost intervention by offering high-accuracy screenings without requiring an ophthalmologist on site.

    The U.S. FDA clearance pathway and the Latin American commercial rollout are advancing in parallel, with Avant playing a key strategic role. Through Ai-nova Acquisition Corp., the company co-founded and structured, Avant holds global licensing rights to Ainnova's platform and stands to benefit from the full spectrum of commercial activity. The Latin America pilot programs—already live and expanding—are expected to deliver measurable near-term revenue, while U.S. approval would unlock a massive new addressable market.

    Meanwhile, Avant is also preparing a new standalone venture that would house a potential therapeutic candidate for diabetes. The goal is to consolidate leadership, data, and IP under one unified structure—eliminating holding company inefficiencies and streamlining execution across diagnostics and treatment.

    Beyond diabetic retinopathy, Ainnova's roadmap includes a cloud-connected retinal camera designed for rural or low-resource clinics, as well as future modules that may detect early signs of Alzheimer's, cardiovascular disease, and other chronic conditions through retinal or blood biomarker analysis. Vision AI could become not just a diagnostic tool, but a frontline system for early detection across multiple diseases.

    The companies continue to explore structural simplification as well. A previously announced non-binding LOI remains active for Avant to acquire 100% of Ainnova Tech—bringing all IP, leadership, and commercial rights under one public umbrella. That move would offer investors direct exposure to the entire tech stack and revenue funnel, while further integrating operations between the two firms.

    CONTINUED... Read this and more news for Avant Technologies at:

    https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    Tevogen Bio Holdings Inc. (NASDAQ:TVGN) and Microsoft Corporation (NASDAQ:MSFT) alongside Databricks, have developed the alpha version of PredicTcell™, a next-gen AI model designed to transform early drug discovery. By dramatically accelerating protein sequence analysis and immunologic target identification, the platform has the potential to save billions in research costs and compress timelines from months to hours.

    "This achievement underscores Tevogen.AI's commitment to revolutionizing therapeutic development through AI-driven innovation," said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. "By significantly accelerating identification of immunologically active targets, PredicTcell enables a more efficient transition into clinical research, ultimately benefiting patients. We look forward to enhancing our datasets to include the spectrum of virology, oncology and neurology to further enhance the PredicTcell platform."

    Built on a terabyte-scale dataset covering nearly a billion genetic and proteomic data points, the system leverages transformer-based AI to improve accuracy and reduce dependency on traditional wet lab testing.

    "Through the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentially resulting in better accuracy and reduced time for wet lab testing," said Dr. Neal Flomenberg, Chief Research and Scientific Officer of Tevogen.

    The initial focus was virology, but the model is now being expanded to cover oncology and potentially neurology. Tevogen believes this foundational platform could yield major gains in both clinical efficiency and commercial opportunity for early adopters.

    Personalis, Inc. (NASDAQ:PSNL), and Tempus AI, Inc. (NASDAQ:TEM) have deepened their collaboration to expand access to AI-powered MRD testing through the NeXT Personal® platform, now adding colorectal cancer to their existing portfolio.

    "This deepened collaboration is a key component of our 'Win in MRD' strategy," said Chris Hall, CEO of Personalis. "Every day, thousands of cancer survivors live with the uncertainty of whether their cancer will return. By expanding our collaboration with Tempus to include CRC, we're bringing peace of mind to more patients while building the evidence needed for broad reimbursement coverage for multiple indications."

    The updated agreement extends through 2029 and aims to accelerate commercial adoption across four key cancer types. Backed by compelling VICTORI study data, the AI-driven test offers ultra-sensitive detection of recurrence, providing oncologists with a more precise and timely monitoring tool.

    "The clinical performance we're seeing across cancer types demonstrates that ultra-sensitive detection fundamentally changes how we can monitor cancer patients," added Hall. "With Tempus' reach to over 50% of U.S. oncologists, we're accelerating access to technology that gives both physicians and patients the information they need when it matters most."

    The collaboration reflects a shared commitment to leveraging AI for personalized, proactive cancer care across multiple stages of treatment.

    Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/  

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo  - https://mma.prnewswire.com/media/2644233/5418904/Equity_Insider_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/from-clinics-to-cancer-labs-ai-is-unlocking-a-new-100b-era-in-medicine-302507340.html

    SOURCE Equity Insider

    Get the next $MSFT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSFT
    $PSNL
    $TEM
    $TVGN

    CompanyDatePrice TargetRatingAnalyst
    Microsoft Corporation
    $MSFT
    10/6/2025$650.00 → $675.00Overweight
    Wells Fargo
    Tempus AI Inc.
    $TEM
    9/2/2025$90.00Buy
    H.C. Wainwright
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $675.00Buy
    Jefferies
    Microsoft Corporation
    $MSFT
    7/31/2025$550.00 → $625.00Overweight
    Barclays
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $650.00Overweight
    Wells Fargo
    Microsoft Corporation
    $MSFT
    7/31/2025$585.00 → $640.00Buy
    BofA Securities
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $630.00Outperform
    Oppenheimer
    Microsoft Corporation
    $MSFT
    7/31/2025$600.00 → $650.00Buy
    UBS
    More analyst ratings

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Fukushima Ryan sold $461,606 worth of shares (5,000 units at $92.32) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    10/8/25 4:15:07 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    EVP, Chief Human Resources Off Coleman Amy was granted 4,358 shares, increasing direct ownership by 9% to 50,282 units (SEC Form 4)

    4 - MICROSOFT CORP (0000789019) (Issuer)

    10/3/25 6:01:06 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    CEO and Chairman Lefkofsky Eric P sold $25,457,014 worth of shares (332,500 units at $76.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/29/25 4:33:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/7/24 4:29:51 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MSFT
    $PSNL
    $TEM
    $TVGN
    SEC Filings

    View All

    Wells Fargo reiterated coverage on Microsoft with a new price target

    Wells Fargo reiterated coverage of Microsoft with a rating of Overweight and set a new price target of $675.00 from $650.00 previously

    10/6/25 8:45:49 AM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    H.C. Wainwright initiated coverage on Tempus AI with a new price target

    H.C. Wainwright initiated coverage of Tempus AI with a rating of Buy and set a new price target of $90.00

    9/2/25 8:40:58 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Jefferies reiterated coverage on Microsoft with a new price target

    Jefferies reiterated coverage of Microsoft with a rating of Buy and set a new price target of $675.00 from $600.00 previously

    7/31/25 8:53:55 AM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 8-K filed by Microsoft Corporation

    8-K - MICROSOFT CORP (0000789019) (Filer)

    9/30/25 4:37:10 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    9/26/25 5:18:10 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    9/26/25 5:15:56 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency's ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers to target metastatic disease, initially focusing on non-small cell lung, breast, and colorectal cancers, with the ultimate goal of improving patient

    10/9/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Microsoft announces quarterly earnings release date

    REDMOND, Wash., Oct. 8, 2025 /PRNewswire/ -- Microsoft Corp. will publish fiscal year 2026 first-quarter financial results after the close of the market on Wednesday, Oct. 29, 2025, on the Microsoft Investor Relations website at https://www.microsoft.com/en-us/Investor/. A live webcast of the earnings conference call will be made available at 2:30 p.m. Pacific Time. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI availab

    10/8/25 4:05:00 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

    10/8/25 10:58:00 AM ET
    $ANIX
    $CTOR
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

    WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Te

    9/10/25 11:59:02 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Circus SE Appoints Former Helsing Top-Executive Sasha Borovik as General Counsel

    Borovik, a Harvard Law graduate, brings 20+ years of legal leadership across AI, tech, and defense, including as Director of Legal Affairs at Microsoft and key legal architect behind defense AI leader Helsing's $5Bn scale-up. He brings deep expertise in global negotiations and IP strategy across commercial and defense sectors - working with customers such as NATO, the UN, and Ukrainian forces. Joins as Circus' first core defense executive to accelerate international growth and legal strategy following the CA-M launch as its first autonomous solution for the defense sector and the CA-1 serial production. Circus SE (XETRA: CA1), a global leader in AI software and robotics for the

    6/11/25 2:11:00 AM ET
    $AKAM
    $MSFT
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/29/25 8:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Financials

    Live finance-specific insights

    View All

    Microsoft announces quarterly earnings release date

    REDMOND, Wash., Oct. 8, 2025 /PRNewswire/ -- Microsoft Corp. will publish fiscal year 2026 first-quarter financial results after the close of the market on Wednesday, Oct. 29, 2025, on the Microsoft Investor Relations website at https://www.microsoft.com/en-us/Investor/. A live webcast of the earnings conference call will be made available at 2:30 p.m. Pacific Time. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI availab

    10/8/25 4:05:00 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Microsoft announces quarterly dividend increase

    Annual shareholders meeting set for Dec. 5, 2025 REDMOND, Wash., Sept. 15, 2025 /PRNewswire/ -- Microsoft Corp. on Monday announced that its board of directors declared a quarterly dividend of $0.91 per share, reflecting an 8 cent or 10% increase over the previous quarter's dividend. The dividend is payable Dec. 11, 2025, to shareholders of record on Nov. 20, 2025. The ex-dividend date will be Nov. 20, 2025. In addition, the company announced the date for the 2025 Annual Shareholders Meeting, to be held Dec. 5, 2025. Shareholders at the close of business on Sept. 30, 2025, the

    9/15/25 6:12:00 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $MSFT
    $PSNL
    $TEM
    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology